Skip to content
Clinical Trials – home
Verifiedinfo

Centre Hospitalier Intercommunal Creteil

France 40 Avenue De Verdun, 94000 Creteil, France

  • 76 trials recruiting
  • Non-small cell lung cancer · Non-small cell lung cancer stage IV · Asthma
  • Adults and children

About Specializations

Centre Hospitalier Intercommunal Creteil in Creteil, France specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer stage IV, Asthma, Non-small cell lung cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms and Oncology Research

At Centre Hospitalier Intercommunal Creteil, clinical trial activity is focused on cancer research, with a strong emphasis on treatments for extensive stage small cell lung cancer. The studies are designed to evaluate whether new treatment approaches can improve patient outcomes and extend survival in this difficult-to-treat disease.

  • Research on extensive stage small cell lung cancer in the first-line setting
  • Evaluation of tarlatamab combined with durvalumab versus durvalumab alone
  • Focus on improving overall survival and treatment effectiveness in advanced lung cancer

This medical oncology program reflects a targeted effort to advance care for aggressive neoplasms through studies that compare new therapeutic strategies with current standard treatment.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
40 Avenue De Verdun94000 CreteilFrance
Recruiting now
76 trials
Conditions studied
122
Partner status
Verified

More sites in CreteilFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

180 clinical trials

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bi 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Bi 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Unicancer
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).